Study | Country/trial start year | Mean age (years)/proportion of male subjects (%) | Regimen/ duration (days) | Eradication rate in treated/non-treated | With precancerous lesion at baseline (%)* | Follow-up period (years) | GC/total in treated vs non-treated | Risk ratio (95% CI) |
Primary prevention | Meta-analysis 0.55 (0.42 to 0.74) | |||||||
Correa et al 28 | Columbia/1994 | 51/46% | BAM/14 days; PAC/14 days (second) | 74% (1st+2nd) /15% | 100% | 6 years | 3/437 vs 2/415 | 1.42 (0.24 to 8.48) |
Leung 2004 and Zhou et al 30 31 | China/1996 | 52/48% | PAC/7 days | 74.5%/9.3% | 44.6% | 10 years | 2/276 vs 7/276 | 0.29 (0.06 to 1.36) |
Wong et al 3 | China/1994 | 42/54% | PAM/14 days | 83.7% | 38.4% | 7.5 years | 7/817 vs 11/813 | 0.63 (0.25 to 1.63) |
Saito et al 32 | Japan/n.a. | 20-59Y/n.a. | PAC/7 days | 74.4% | NA | ≥4 years | 2/379 vs 3/313 | 0.55 (0.09 to 3.27) |
Ma et al and Li et al 33 34 | China/1995 | 47/50% | PA/14 days | 74%/NA Y7: 46%/10% | 75.7% | 22 years | 41/1130 vs 78/1128 | 0.52 (0.36 to 0.76) |
Wong et al 35 | China/2002 | 53/46% | PAC/7 days | 71.3%/NA | 100% | 5 years | 6/510 vs 3/514 | 2.02 (0.51 to 8.02) |
Choi et al 5 | Korea/2012 | 49/50% | PAC/7 days | 70.1%/7.1% | 57.4% | 9 years | 10/912 vs 23/914 | 0.44 (0.21 to 0.91) |
Secondary prevention | Meta-analysis 0.48 (0.33 to 0.69) | |||||||
Fukase et al 38 | Japan/2001 | 69/76% | PAC/7 days | 74.9%/5% | 75%/49% | 3 years | 8/272 vs 24/272 | 0.33 (0.15 to 0.73) |
Choi et al 39 | Korea/2005 | 60/68% | PAC/7 days | 82.6%/10.5% | 66.1%/75.7% | 6 years | 18/444 vs 36/457 | 0.52 (0.30 to 0.89) |
Choi et al 4 | Korea/2003 | 60/75% | PAC/7 days | 80.4%/5.4% | 80.2%/54.7% | 6 years | 14/194 vs 27/202 | 0.54 (0.29 to 1.00) |
*the extent and severity of precancerous lesions varied among studies.
BAM, bismuth, amoxicillin and metronidazole; GC, gastric cancer; NA, not available; PAC, proton pump inhibitor, amoxicillin, clarithromycin; 1st+2nd, overall eradication rates.